0.252
-0.01 (-3.19%)
| Previous Close | 0.260 |
| Open | 0.252 |
| Volume | 366,019 |
| Avg. Volume (3M) | 938,318 |
| Market Cap | 8,357,645 |
| Price / Book | 0.340 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -2.65 |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | -51.76 M |
| Levered Free Cash Flow (TTM) | -23.85 M |
| Return on Assets (TTM) | -73.14% |
| Return on Equity (TTM) | -132.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Relmada Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.33 |
|
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 17.02% |
| % Held by Institutions | 33.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Parsons Capital Management Inc/Ri | 31 Dec 2024 | 163,336 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 May 2025 | Announcement | Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 |
| 28 Apr 2025 | Announcement | Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 |
| 27 Apr 2025 | Announcement | UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 |
| 24 Apr 2025 | Announcement | Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data |
| 14 Apr 2025 | Announcement | Relmada Therapeutics To Present NDV-01 Data at AUA2025 |
| 27 Mar 2025 | Announcement | Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update |
| 26 Mar 2025 | Announcement | Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 |
| 25 Mar 2025 | Announcement | Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |